Clinical trials: Epileptic Seizures
Epilepsy
Validation of a Seizure Monitoring System
The investigators aim to determine the feasibility of using the Medtronic LINQ device for epilepsy diagnosis, monitoring and management.
- Trial name
- NCT03465189
- Testing
- Medtronic LINQ Device
- Where
- Australia
- Volunteers
- 10 people
- Sponsor
- St Vincent's Hospital Melbourne
Epilepsy
The Benefits of a Care Pathway Combining Remote Monitoring and Support From a Nurse After a Change in Anti-epileptic Treatment: a Pilot Study
Epilepsy is a chronic condition affecting approximately 600,000 people in France. Epilepsy treatment relies on antiepileptic drugs, the effectiveness of which depends on adherence to medication schedule, with missed doses…
- Trial name
- EPISUR (NCT07507240)
- Testing
- Remote monitoring training, Description of the standard care pathway, Therapeutic support with a nurse
- Where
- France
- Volunteers
- 60 people
- Sponsor
- University Hospital, Toulouse
Epilepsy, Cancer
Tumor Related Epilepsy
Background: Some people with brain tumors have seizures related to the tumor. This is called tumor-related epilepsy. Usually brain tumors are treated by removing as much of the brain tumor as possible without causing problems.
- Conditions
- Epilepsy, Cancer, Brain Neoplasm
- Trial name
- NCT02639325
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Temporal Lobe Epilepsy (TLE), Drug Resistant Epilepsy
Overnight TI in TLE
The goal of this clinical trial is to gauge whether overnight, non-invasive temporal interference (TI) stimulation aimed at the hippocampus can reduce abnormal brain activity linked to seizures and improve sleep in adults with…
- Conditions
- Temporal Lobe Epilepsy (TLE), Drug Resistant Epilepsy, Sleep
- Trial name
- TI-HPC-TLE (NCT07434986)
- Testing
- Non-invasive Temporal Interference (TI) Stimulation Targeting Bilateral Hippocampi
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Duke University
Unverricht-Lundborg Disease
Brivaracetam as add-on Treatment of Unverricht-Lundborg Disease (ULD) in Adolescents and Adults
The study will compare the efficacy and safety of Brivaracetam with placebo in patients with Unverricht- Lundborg Disease (ULD).
- Trial name
- NCT00368251
- Testing
- BRV 2.5 mg, BRV 25 mg, BRV 50 mg
- Where
- 18 sites in United States, Canada and 6 more
- Volunteers
- 56 people
- Sponsor
- UCB Pharma
MEF2C, DEE
Genetic Developmental and Epileptic Encephalopathy Natural History Study for Clinical Trial Readiness
Phase 0 non-interventional longitudinal study of children and adults with Developmental and Epileptic Encephalopathy (DEE) due to a genetic cause. There are six arms of the study.
- Trial name
- NCT07413211
- Testing
- Observation
- Where
- United States
- Volunteers
- 22,068 people
- Sponsor
- Weill Medical College of Cornell University
Cardiovascular Diseases, Cardiovascular Diseases Risk
Cor360: Clinician-Facing Broad-Spectrum Cardiac Phenotyping and Risk Assessment Using COR® Wearable ECG to Inform Outcomes-Oriented Care Pathways
Cor360 is an observational study evaluating whether extended wearable electrocardiogram (ECG) data can support broad-spectrum cardiac phenotyping and risk assessment beyond conventional single-purpose ambulatory rhythm…
- Conditions
- Cardiovascular Diseases, Cardiovascular Diseases Risk, Cardiac Conduction System Disease, Bundle/Fascicular Abnormalities
- Trial name
- Cor360 (NCT07775976)
- Testing
- COR Wearable ECG Monitoring, Cor360 Clinician-Facing Decision-Aid Reporting
- Where
- 2 sites in United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Peerbridge Health, Inc
Epilepsy, Temporal Lobe, Amygdalo-Hippocampal Epilepsy
EASINESS-TRIAL - Enhancing Safety in Epilepsy Surgery
To conduct a retrospective multicenter cohort study to define surgical benchmark values for best achievable outcomes following surgery for mesial temporal lobe epilepsy.
- Trial name
- NCT04952298
- Testing
- Mesial temporal lobe epilepsy surgery
- Where
- Germany
- Volunteers
- 1,500 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Epilepsy, Dravet Syndrome
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-935 (OV935) as an Adjunctive Therapy in Pediatric Participants With Developmental and/or Epileptic Encephalopathies
The purpose of this study is to investigate the effect on the frequency of all seizures (convulsive and drop) in participants treated with TAK-935 compared to placebo.
- Conditions
- Epilepsy, Dravet Syndrome, Lennox-Gastaut Syndrome
- Trial name
- ELEKTRA (NCT03650452)
- Testing
- TAK-935
- Where
- 44 sites in United States, Australia and 6 more
- Volunteers
- 141 people
- Sponsor
- Takeda
Epilepsy
Optimization of the Parameters of Vagal Nerve Stimulation
Vagal nerve stimulation (VNS) is one of the neuromodulation techniques that can be indicated in patients suffering from refractory epilepsies, especially when an open resection has failed or is not indicated.
- Trial name
- OPSTIMVAG (NCT04693221)
- Testing
- Choice of VNS set of parameters based on the lowest PLI, EEG
- Where
- 18 sites in France
- Volunteers
- 140 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Partial Seizures
Pregabalin Versus Levetiracetam In Partial Seizures
This study will compare pregabalin and levetiracetam in patients with partial seizures. It will also evaluate the safety and tolerability of pregabalin and levetiracetam in these patients.
- Trial name
- NCT00537238
- Testing
- pregabalin, levetiracetam
- Where
- 72 sites in Belgium, Bulgaria and 19 more
- Volunteers
- 509 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Heart Rate, Nocturnal Seizures
Heart Rate Variability (HRV) Analysis in Patients With Nocturnal Epileptic Seizures
Epilepsy is disabling and costly to patients and the health service. Nearly 400,000 people in England suffer from epilepsy. About 40% of these patients are known to have seizures predominantly in sleep.
- Conditions
- Heart Rate, Nocturnal Seizures, Autonomic Nervous System, Epilepsy
- Trial name
- NCT02469844
- Where
- United Kingdom
- Volunteers
- 48 people
- Sponsor
- Sheffield Teaching Hospitals NHS Foundation Trust
Seizure in Participants With Tuberous Sclerosis Complex, Seizure in Participants With Dravet Syndrome
Assessment of Adjunctive Cannabidiol Oral Solution (GWP42003-P) in Children With Tuberous Sclerosis Complex (TSC), Dravet Syndrome (DS), or Lennox-Gastaut Syndrome (LGS) Who Experience Inadequately-controlled Seizures
This study will be conducted to evaluate the safety, pharmacokinetics (PK), and efficacy of adjunctive GWP42003-P in participants < 2 years of age with tuberous sclerosis complex (TSC), Lennox-Gastaut syndrome (LGS), or Dravet…
- Conditions
- Seizure in Participants With Tuberous Sclerosis Complex, Seizure in Participants With Dravet Syndrome, Seizure in Participants With Lennox-Gastaut Syndrome
- Trial name
- NCT04485104
- Testing
- GWP42003-P
- Where
- 11 sites in United States, Italy and 1 more
- Volunteers
- 3 people
- Sponsor
- Jazz Pharmaceuticals
Attention Deficit Disorder With Hyperactivity, Epilepsy
Methylphenidate for Treating Attention Deficit Hyperactivity Disorder in Children With Both ADHD and Epilepsy
This study will evaluate the safety and effectiveness of extended release methylphenidate (XR-MPH) in treating attention deficit hyperactivity disorder (ADHD) in children with both ADHD and epilepsy.
- Trial name
- NCT00323947
- Testing
- Extended Release Methylphenidate (OROS-Methylphenidate)
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Boston Children's Hospital
Dravet Syndrome
Safety and Tolerability of Clobazam as Adjunctive Therapy in Paediatric Patients Aged ≥1 to ≤16 Years With Dravet Syndrome
To investigate the long-term safety and tolerability of clobazam when administered for 1 year as adjunctive therapy in paediatric patients aged ≥1 to ≤16 years with Dravet Syndrome.
- Trial name
- NCT02187809
- Testing
- Clobazam
- Where
- 9 sites in United States, Mexico
- Volunteers
- 3 people
- Sponsor
- H. Lundbeck A/S
Benign Epilepsy With Centro Temporal Spikes (BECTS), Atypical Benign Partial Epilepsy (ABPE)
Sleep Related Memory Consolidation in Children With Age Related Focal Epilepsy.
Age related focal epilepsies in children encompasses, according to the ILAE criteria, benign epilepsy with centro temporal spikes (BECTS), atypical benign partial epilepsy (ABPE) and epileptic encephalopathy with continuous spike…
- Conditions
- Benign Epilepsy With Centro Temporal Spikes (BECTS), Atypical Benign Partial Epilepsy (ABPE), Epileptic Encephalopathy With Continuous Spike and Waves During Sleep (ECSWS)
- Trial name
- EPIMEM (NCT03865771)
- Testing
- Neuropsychological testing, Neuropsychological procedure, Video EEG and polysomnography
- Where
- 2 sites in France
- Volunteers
- 95 people
- Sponsor
- University Hospital, Strasbourg, France
Epilepsy, Partial
Long-Term, Follow-Up Study Of the Safety And Efficacy Of Levetiracetam In Children With Partial Onset Seizures
To allow pediatric patients with partial onset seizures an opportunity to receive (as follow-up to studies N01009(NCT00105040)/N01103(NCT00175890) or by direct enrollment) open-label levetiracetam treatment, continue studying…
- Trial name
- NCT00152516
- Testing
- levetiracetam (LEV)
- Where
- 84 sites in United States, Belgium and 14 more
- Volunteers
- 255 people
- Sponsor
- UCB Pharma
Partial Epilepsy
A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures
This is a multicenter, double-blind, randomized, placebo-controlled dose response study, with an 8-week prospective baseline and an 18 week double-blind treatment period (including a 6-week titration phase and 12 week maintenance…
- Trial name
- NCT01866111
- Testing
- YKP3089
- Where
- 67 sites in United States, Australia and 13 more
- Volunteers
- 437 people
- Sponsor
- SK Life Science, Inc.
Dravet Syndrome
Transcranial Magnetic Stimulation to Measure Cortical Excitability in Dravet Syndrome
Dravet syndrome (DS) is an epileptic encephalopathy caused by pathogenic variants in the SCN1A gene resulting in medically refractory epilepsy and psychomotor delays.
- Trial name
- NCT04614506
- Testing
- Transcranial Magnetic Stimulation (TMS), Electroencephalogram (EEG)
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Boston Children's Hospital
Epilepsy
ZAGAL Study: Evaluating Effectiveness and Tolerability of Zonisamide as Adjunctive Therapy in Patients With Partial Onset Seizures Treated With Two Antiepileptic Drugs
The purpose of this study is to acquire additional information about the appropriate level of dosing of Zonisamide when it is prescribed for patients with partial onset epileptic crisis who are already being treated with two…
- Trial name
- NCT00659958
- Testing
- Zonisamide
- Where
- 11 sites in Spain
- Volunteers
- 32 people
- Sponsor
- Eisai Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.